[1]沙金平,徐　赟,刁云辉.重组人血管内皮抑制素注射液和三维适形调强放射治疗联合治疗食管癌疗效观察[J].新乡医学院学报,2022,39(2):149-154.[doi:10.7683/xxyxyxb.2022.02.010]
　SHA Jinping,XU Yun,DIAO Yunhui.Effect of recombinant human endostatin injection combined with three-dimensional conformal modulating radiotherapy in the treatment of esophageal cancer[J].Journal of Xinxiang Medical University,2022,39(2):149-154.[doi:10.7683/xxyxyxb.2022.02.010]
点击复制

重组人血管内皮抑制素注射液和三维适形调强放射治疗联合治疗食管癌疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年2
页码:
149-154
栏目:
临床研究
出版日期:
2022-02-05

文章信息/Info

Title:
Effect of recombinant human endostatin injection combined with three-dimensional conformal modulating radiotherapy in the treatment of esophageal cancer
作者:
沙金平; 徐　赟; 刁云辉
（南阳市中心医院消化内科，河南　南阳　473000）
Author(s):
SHA Jinping; XU Yun; DIAO Yunhui
(Department of Gastroenterology,Nanyang Central Hospital,Nanyang 473000,Henan Province,China)
关键词:
食管癌; 重组人血管内皮抑制素注射液; 三维适形调强放射治疗; 肿瘤标志物; 免疫功能
Keywords:
esophageal cancer; recombinant human endostatin injection; three-dimensional conformal modulating radiotherapy; tumor markers; immune function
分类号:
R735.1
DOI:
10.7683/xxyxyxb.2022.02.010
文献标志码:
A
摘要:
目的　探讨重组人血管内皮抑制素注射液和三维适形调强放射治疗联合治疗食管癌的临床效果。方法　选择2017年6月至2020年2月南阳市中心医院收治的86例食管癌患者为研究对象，采用随机数字表法将患者分为观察组和对照组，每组43例。2组患者均给予营养支持、保肝、抑酸等常规治疗措施，在常规治疗基础上，对照组患者给予三维适形调强放射治疗，观察组患者给予重组人血管内皮抑制素注射液和三维适形调强放射治疗联合治疗。治疗后评估2组患者治疗效果，并观察治疗期间患者不良反应发生情况。对2组患者治疗前后血清中癌胚抗原（CEA）、细胞角质蛋白19片段抗原21-1（CYFRA21-1）、鳞状上皮细胞癌抗原（SCCA）、血管内皮生长因子（VEGF）、表皮生长因子受体（EGFR）、转化生长因子-β1（TGF-β1）水平及外周血CD4+、CD8+、CD4+/CD8+水平和患者生活质量量表（QLQ-30）评分进行比较。结果　观察组和对照组患者总有效率分别为72.09%（31/43）、51.16%（22/43），观察组患者治疗总有效率显著高于对照组（χ2=3.983，P<0.05）。治疗期间，观察组患者放射性食管炎、血液毒性、食管狭窄、气管炎的发生率分别为30.23%（13/46）、13.95%（6/46）、2.33%（1/46）、9.30%（4/46），对照组患者放射性食管炎、血液毒性、食管狭窄、气管炎的发生率分别为53.49%（23/46）、32.56%（14/46）、4.65%（2/46）、20.93%（9/46）；观察组患者放射性食管炎、血液毒性发生率显著低于对照组（χ2=4.778、4.170，P<0.05），2组患者食管狭窄、气管炎发生率比较差异无统计学意义（χ2=0.001、2.266，P>0.05）。2组患者治疗前血清CEA、CYFRA21-1、SCCA水平比较差异无统计学意义（P>0.05）；2组患者治疗后血清CEA、CYFRA21-1、SCCA水平显著低于治疗前（P<0.05）；治疗后，观察组患者血清CEA、CYFRA21-1、SCCA水平显著低于对照组（P<0.05）。2组患者治疗前CD4+、CD8+、CD4+/CD8+水平比较差异无统计学意义（P>0.05），观察组患者治疗前后CD4+、CD8+、CD4+/CD8+水平比较差异无统计学意义（P>0.05）；与治疗前比较，对照组患者治疗后CD4+、CD4+/CD8+水平显著降低，CD8+水平显著升高（P<0.05）。治疗后，观察组患者CD4+、CD4+/CD8+水平显著高于对照组，CD8+水平显著低于对照组（P<0.05）。2组患者治疗前血清VEGF、EGFR、TGF-β1水平比较差异无统计学意义（P>0.05），2组患者治疗后血清VEGF、EGFR、TGF-β1水平显著低于治疗前（P<0.05）；治疗后，观察组患者血清VEGF、EGFR、TGF-β1水平显著低于对照组（P<0.05）。2组患者治疗前QLQ-30评分比较差异无统计学意义（P>0.05），2组患者治疗后QLQ-30评分显著高于治疗前（P<0.05）；治疗后，观察组患者QLQ-30评分显著高于对照组（P<0.05）。结论　重组人血管内皮抑制素注射液联合三维适形调强放射治疗可有效下调血清肿瘤标志物表达，抑制肿瘤生长，改善患者免疫功能和生存质量，降低不良反应发生率。
Abstract:
Objective　To investigate the clinical effect of recombinant human endostatin injection combined with three-dimensional conformal modulating radiotherapy in the treatment of esophageal cancer.Methods　A total of 86 patients with esophageal cancer treated in Nanyang Central Hospital from June 2017 to February 2020 were selected as the research subjects,and the patients were divided into observation group and control group by random number table,with 43 cases in each group.The patients in the two groups were treated with routine treatment measures such as nutritional support,liver protection and acid suppression.On the basis of routine treatment,the patients in the control group were treated with three-dimensional conformal modulating radiotherapy,and the patients in the observation group were treated with recombinant human endostatin injection and three-dimensional conformal modulating radiotherapy.The therapeutic effects of patients in the two groups were evaluated after treatment,and the occurrence of adverse reactions during treatment was observed.The levels of carcinoembryonic antigen (CEA),cytokeratin 19 fragment antigen 21-1 (CYFRA21-1),squamous cell carcinoma antigen (SCCA),vascular endothelial growth factor (VEGF),epidermal growth factor receptor (EGFR),transforming growth factor-β1 (TGF-β1) in serum and CD4+,CD8+,CD4+/CD8+ in peripheral blood and quality of life questionnaire 30(QLQ-30) scores were compared between the two groups before and after treatment.Results　The total effective rate in the observation group and control group was 72.09% (31/43) and 51.16% (22/43),respectively.The total effective rate in the observation group was significantly higher than that in the control group (χ2=3.983,P<0.05).During the treatment,the incidence rates of radiation esophagitis,hematotoxicity,esophageal stenosis and tracheitis in the observation group were 30.23% (13/46),13.95% (6/46),2.33% (1/46) and 9.30% (4/46),respectively.The incidence rates of radiation esophagitis,hematotoxicity,esophageal stenosis and tracheitis in the control group were 53.49% (23/46),32.56% (14/46),4.65% (2/46),20.93%(9/46),respectively.The incidence rates of radiation esophagitis and hematotoxicity in the observation group were significantly lower than those in the control group (χ2= 4.778,4.170;P<0.05).There was no significant difference in the incidences of esophageal stenosis and tracheitis between the two groups (χ2=0.001,2.266;P>0.05).There was no significant difference in serum CEA,CYFRA21-1 and SCCA levels between the two groups before treatment (P>0.05).The levels of serum CEA,CYFRA21-1 and SCCA after treatment were significantly lower than those before treatment in the two groups (P<0.05).The levels of serum CEA,CYFRA21-1 and SCCA in the observation group were significantly lower than those in the control group after treatment (P<0.05).There was no significant difference in the levels of CD4+,CD8+,CD4+/CD8+ between the two groups before treatment (P>0.05).There was no significant difference in the levels of CD4+,CD8+,CD4+/CD8+ in the observation group before and after treatment (P>0.05).Compared with before treatment,the levels of CD4+,CD4+/CD8+ in the control group decreased significantly after treatment,and the level of CD8+ increased significantly (P<0.05).After treatment,the levels of CD4+,CD4+/CD8+ in the observation group were significantly higher than those in the control group,and the level of CD8+ was significantly lower than that in the control group (P<0.05).There was no significant difference in the levels of serum VEGF,EGFR and TGF-β1 between the two groups before treatment (P>0.05).The levels of serum VEGF,EGFR and TGF-β1 after treatment were significantly lower than those before treatment in the two groups (P<0.05).After treatment,the levels of serum VEGF,EGFR and TGF-β1 in the observation group were significantly lower than those in the control group (P<0.05).There was no significant difference in QLQ-30 score of patients between the two groups before treatment (P>0.05).The QLQ-30 score of patients after treatment was significantly higher than that before treatment in the two groups (P<0.05).After treatment,the QLQ-30 score of patients in the observation group was significantly higher than that in the control group (P<0.05).Conclusion　Recombinant human endostatin injection combined with three-dimensional conformal modulating radiotherapy can effectively down regulate the expression of serum tumor markers,inhibit tumor growth,improve patients′ immune function and quality of life,and reduce the incidence of adverse reactions.

参考文献/References:

［1］　WANG C,LU M,ZHOU T T,et al.Intensity-modulated radiotherapy does not decrease the risk of malnutrition in esophageal cancer patients during radiotherapy compared to three-dimensional conformal radiation therapy［J］.J Thorac Dis,2019,11(9):3721-3731.
［2］　CHEN N B,QIU B,ZHANG J,et al.Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in definitive chemoradiotherapy for cervical esophageal squamous cell carcinoma:comparison of survival outcomes and toxicities［J］.Cancer Res Treat,2020,52(1):31-40.
［3］　LIN W C,CHANG C L,HSU H L,et al.Three-dimensional conformal radiotherapy-based or intensity-modulated radiotherapy-based concurrent chemoradiotherapy in patients with thoracic esophageal squamous cell carcinoma［J］.Cancers(Basel),2019,11(10):1529.
［4］　TAN L,XIAO Z,ZHANG H,et al.Survival comparision of three-dimensional radiotherapy alone with concurrent chemoradiotherapy for non-surgical esophageal carcinoma［J］.Cancer Radiother,2020,24(1):21-27.
［5］　WANG J,YU J P,WANG J L,et al.Thalidomide combined with chemoradiotherapy for treating esophageal cancer:a randomized controlled study［J］.Oncol Lett,2019,18(1):804-813.
［6］　ZHENG W,FU L.Effect of thalidomide combined with TP chemotherapy on serum VEGF and NRP-1 levels advanced esophageal cancer patients［J］.Am J Transl Res,2021,13(9):10809-10815.
［7］　LORDICK F,MARIETTE C,HAUSTERMANS K,et al.Oesophageal cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up［J］.Ann Oncol,2016,27(Suppl 5):v50-v57.
［8］　中国医师协会放射肿瘤治疗医师分会，中华医学会放射肿瘤治疗学分会，中国抗癌协会肿瘤放射治疗专业委员会.中国食管癌放射治疗指南(2019年版)［J］.国际肿瘤学杂志，2019， 46（7）：385-398.
CHINESE MEDICAL DOCTOR ASSOCIATION RADIATION ONCOLOGY PHYSICIAN BRANCH,CHINESE MEDICAL ASSOCIATION RADIATION ONCOLOGY BRANCH,CHINESE ANTI-CANCER ASSOCIATION CANCER RADIATION THERAPY PROFESSIONAL COMMITTEE.Chinese guidelines for radiation therapy of esophageal cancer 2019［J］.J Int Oncol,2019,46(7):385-398.
［9］　HAQUE W,VERMA V,BUTLER E B,et al.Trimodality therapy for esophageal cancer at high volume facilities is associated with improved postoperative outcomes and overall survival［J］.Dis Esophagus,2019,32(4):1-8.
［10］　YOSHIO K,WAKITA A,MITSUHASHI T,et al.Simultaneous integrated boost volumetric modulated arc therapy for middle or lower esophageal cancer using elective nodal irradiation:comparison with 3D conformal radiotherapy［J］.Acta Med Okayama,2019,73(3):247-257.
［11］　孟令新，韩菁，周丹丹，等.中下段食管鳞癌患者行三维适形调强放射疗法与发生放射性肺损伤的相关性［J］.中国医药，2018，13（1）：80-84.
MENG L X,HAN J,ZHOU D D,et al.Correlation between three-dimensional conformal intensity-modulated radiation therapy and radiation-induced lung injury in patients with middle and lower esophageal squamous cell carcinoma［J］.Chin Med,2018,13(1):80-84.
［12］　AMARE G G,MEHARIE B G,BELAYNEH Y M.A drug repositioning success:the repositioned therapeutic applications and mechanisms of action of thalidomide［J］.J Oncol Pharm Pract,2021,27(3):673-678.
［13］　闻杨，董洪敏，王文玲，等.重组人血管内皮抑制素联合化疗对晚期结直肠癌的疗效［J］.中国现代医学杂志，2018，28（30）：109-114.
WEN Y,DONG H M,WANG W L,et al.Efficacy of recombinant human endostatin combined with chemotherapy on advanced colorectal cancer［J］.Chin J Mod Med,2018,28(30):109-114.
［14］　WANG Z Q,WANG D S,WANG F H,et al.Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma:a prospective,single-arm,open-label,phase Ⅱ study［J］.Invest New Drugs,2021,39(2):516-523.
［15］　陈群，石琴，谢强.恩度同步放疗治疗不能手术局部晚期老年非小细胞肺癌的临床疗效［J］.中国癌症防治杂志,2017,9(2):142-145.
CHEN Q,SHI Q,XIE Q.Clinical efficacy of endo-synchronous radiotherapy in the treatment of inoperable locally advanced non-small cell lung cancer［J］.Chin J Oncol Prev Treat,2017,9(2):142-145.
［16］　LIAO X Y,LIU C Y,HE J F,et al.Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment:a novel strategy［J］.Oncol Lett,2019,18(5):5011-5021.
［17］　LV Y J,SONG M J,TIAN X F,et al.Impact of radiotherapy on circulating lymphocyte subsets in patients with esophageal cancer［J］.Medicine(Baltimore),2020,99(36):e20993.
［18］　南海峰，丁磊.消癌平注射液联合沙利度胺辅助放化疗对中晚期食管癌患者肿瘤标志物、血管内皮生长因子及其受体表达的影响［J］.世界中医药，2019，14（2）：407-411.
NAN H F,DING L.Effects of Xiaoaiping injection combined with thalidomide adjuvant radiotherapy and chemoradiotherapy on the expression of tumor markers,VEGF and its receptors in patients with middle and late advanced esophageal cancer［J］.World Chin Med,2019,14 (02):407-411.
［19］　胡金华，张耀晴，朱斌.食管癌患者血清VEGF、TNF-α和IL-6表达与预后的相关性［J］.现代肿瘤医学，2017，25（1）：63-66.
HU J H,ZHANG Y Q,ZHU B.Correlation of serum VEGF,TNF-α and IL-6 and prognosis of patients with esophageal cancer［J］.Mod Oncol,2017,25(1):63-66.
［20］　高艳梅，杨怡萍，慕玉东，等.EGFR、XRCC3、hOGG1在食管癌中的表达及其与放疗敏感性的关系［J］.实用癌症杂志，2018，33（7）：1061-1064.
GAO Y M,YANG Y P,MU Y D,et al.The relationships between expressions of EGFR、XRCC3 and hOGGl and radiosensitivity in esophageal cancer［J］.Pract J Cancer,2018,33(7):1061-1064.
［21］　李冲，白露，龚玉竹.血清IGF-1、TGF-β1在食管癌患者中的水平及意义［J］.中华保健医学杂志，2019，21（4）：341-343.
LI C,BAI L,GONG Y Z.The level and significance of serum IGF-1 and TGF-β1 in patients with esophageal cancer［J］.Chin J Health Med,2019,21(4):341-343.
［22］　王莉，潘艳东.VEGF与肿瘤放射抗拒的研究进展［J］.临床医学工程，2017，24（8）：1183-1184.
WANG L,PAN Y D.Advance in the research of VEGF and tumor radiation resistance［J］.Clin Med Eng,2017,24(8):1183-1184.

相似文献/References:

[1]原志庆,王凤荣,吴国祥,等.食管癌切除标本断端残留癌的流式细胞分析[J].新乡医学院学报,1991,8(01):012.
[2]彭明轩,张一峰.食管癌与贲门癌238例手术治疗及其并发症分析[J].新乡医学院学报,1992,9(01):048.
[3]刘玉梅,申维玺,姚卫华,等.氟尿嘧啶合并醛氢叶酸治疗食管癌疗效评价[J].新乡医学院学报,1995,12(02):123.
[4]原志庆,许春雷.瘤体内DNA倍体异质性与食管鳞状细胞癌病理特性的关系[J].新乡医学院学报,1995,12(01):005.
[5]常银江,马森林,王守义,等.上段食管癌切除后食管床内胃食管颈部吻合术[J].新乡医学院学报,1996,13(02):143.
[6]王俊英,李国群,董长宪,等.食管癌合并糖尿病患者的围手术期处理[J].新乡医学院学报,1996,13(02):151.
[7]陈国荣.中晚期食管癌夹心治疗近期疗效分析 [J].新乡医学院学报,1997,14(02):150.
[8]李慧清,李汉臣,杨红伟,等.不同食管胃吻合方法术后生活质量分析[J].新乡医学院学报,1997,14(03):213.
[9]郭玉军,吴阶清,刘新秋,等.双介入疗法治疗晚期食管癌[J].新乡医学院学报,1997,14(03):287.
[10]乔　刚　李汉臣　席红军　王忠民　崔　玉　韩培立　赵宝生.食管癌患者手术前后细胞免疫的变化[J].新乡医学院学报,1999,16(04):308.

更新日期/Last Update: 2022-02-05